Cargando…

The Clinical Application of Core-Needle Biopsy after Radiofrequency Ablation for Low-risk Papillary Thyroid Microcarcinoma: A Large Cohort of 202 Patients Study

Purpose: To evaluate the clinical application of core-needle biopsy (CNB) for low-risk papillary thyroid microcarcinoma (PTMC) after radiofrequency ablation (RFA) Methods: A total of 202 patients with 211 low-risk PTMCs were included in this study. RFA procedure was used the hydrodissection techniqu...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Lin, Luo, Yukun, Zhang, Ying, Zhu, Yaqiong, Xiao, Jing, Lan, Yu, Tian, Xiaoqi, Song, Qing, Xie, Fang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7391195/
https://www.ncbi.nlm.nih.gov/pubmed/32742471
http://dx.doi.org/10.7150/jca.42673
_version_ 1783564589725646848
author Yan, Lin
Luo, Yukun
Zhang, Ying
Zhu, Yaqiong
Xiao, Jing
Lan, Yu
Tian, Xiaoqi
Song, Qing
Xie, Fang
author_facet Yan, Lin
Luo, Yukun
Zhang, Ying
Zhu, Yaqiong
Xiao, Jing
Lan, Yu
Tian, Xiaoqi
Song, Qing
Xie, Fang
author_sort Yan, Lin
collection PubMed
description Purpose: To evaluate the clinical application of core-needle biopsy (CNB) for low-risk papillary thyroid microcarcinoma (PTMC) after radiofrequency ablation (RFA) Methods: A total of 202 patients with 211 low-risk PTMCs were included in this study. RFA procedure was used the hydrodissection technique and moving-shot technique. Patients were followed at 1, 3, 6, 12 months and every 6 months thereafter. The volume of ablation area and the volume reduction ratio (VRR) were calculated. At 3 or 6 months after RFA, CNB was performed to the central zone, the peripheral zone and surrounding thyroid parenchyma for post-ablation evaluation. Results: The mean volume of tumors was 102.34±93.84 mm(3) (range 4.19-424.10 mm(3)), which decreased significantly to 1.37±7.74 mm(3) (range 0-73.30 mm(3)) at a mean follow-up time of 24.42±9.15 months (range 3-42 months) with a mean VRR of 99.14±4.18% (range 71.88-100%). A total of 3 ablation areas had positive CNB in the peripheral zone and underwent additional RFA. No recurrent or suspicious metastatic lymph nodes were detected Conclusion: CNB is a feasible and effective evaluation for low-risk PTMC after RFA, which can detect residual cancer cells early.
format Online
Article
Text
id pubmed-7391195
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-73911952020-07-31 The Clinical Application of Core-Needle Biopsy after Radiofrequency Ablation for Low-risk Papillary Thyroid Microcarcinoma: A Large Cohort of 202 Patients Study Yan, Lin Luo, Yukun Zhang, Ying Zhu, Yaqiong Xiao, Jing Lan, Yu Tian, Xiaoqi Song, Qing Xie, Fang J Cancer Research Paper Purpose: To evaluate the clinical application of core-needle biopsy (CNB) for low-risk papillary thyroid microcarcinoma (PTMC) after radiofrequency ablation (RFA) Methods: A total of 202 patients with 211 low-risk PTMCs were included in this study. RFA procedure was used the hydrodissection technique and moving-shot technique. Patients were followed at 1, 3, 6, 12 months and every 6 months thereafter. The volume of ablation area and the volume reduction ratio (VRR) were calculated. At 3 or 6 months after RFA, CNB was performed to the central zone, the peripheral zone and surrounding thyroid parenchyma for post-ablation evaluation. Results: The mean volume of tumors was 102.34±93.84 mm(3) (range 4.19-424.10 mm(3)), which decreased significantly to 1.37±7.74 mm(3) (range 0-73.30 mm(3)) at a mean follow-up time of 24.42±9.15 months (range 3-42 months) with a mean VRR of 99.14±4.18% (range 71.88-100%). A total of 3 ablation areas had positive CNB in the peripheral zone and underwent additional RFA. No recurrent or suspicious metastatic lymph nodes were detected Conclusion: CNB is a feasible and effective evaluation for low-risk PTMC after RFA, which can detect residual cancer cells early. Ivyspring International Publisher 2020-07-09 /pmc/articles/PMC7391195/ /pubmed/32742471 http://dx.doi.org/10.7150/jca.42673 Text en © The author(s) This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Research Paper
Yan, Lin
Luo, Yukun
Zhang, Ying
Zhu, Yaqiong
Xiao, Jing
Lan, Yu
Tian, Xiaoqi
Song, Qing
Xie, Fang
The Clinical Application of Core-Needle Biopsy after Radiofrequency Ablation for Low-risk Papillary Thyroid Microcarcinoma: A Large Cohort of 202 Patients Study
title The Clinical Application of Core-Needle Biopsy after Radiofrequency Ablation for Low-risk Papillary Thyroid Microcarcinoma: A Large Cohort of 202 Patients Study
title_full The Clinical Application of Core-Needle Biopsy after Radiofrequency Ablation for Low-risk Papillary Thyroid Microcarcinoma: A Large Cohort of 202 Patients Study
title_fullStr The Clinical Application of Core-Needle Biopsy after Radiofrequency Ablation for Low-risk Papillary Thyroid Microcarcinoma: A Large Cohort of 202 Patients Study
title_full_unstemmed The Clinical Application of Core-Needle Biopsy after Radiofrequency Ablation for Low-risk Papillary Thyroid Microcarcinoma: A Large Cohort of 202 Patients Study
title_short The Clinical Application of Core-Needle Biopsy after Radiofrequency Ablation for Low-risk Papillary Thyroid Microcarcinoma: A Large Cohort of 202 Patients Study
title_sort clinical application of core-needle biopsy after radiofrequency ablation for low-risk papillary thyroid microcarcinoma: a large cohort of 202 patients study
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7391195/
https://www.ncbi.nlm.nih.gov/pubmed/32742471
http://dx.doi.org/10.7150/jca.42673
work_keys_str_mv AT yanlin theclinicalapplicationofcoreneedlebiopsyafterradiofrequencyablationforlowriskpapillarythyroidmicrocarcinomaalargecohortof202patientsstudy
AT luoyukun theclinicalapplicationofcoreneedlebiopsyafterradiofrequencyablationforlowriskpapillarythyroidmicrocarcinomaalargecohortof202patientsstudy
AT zhangying theclinicalapplicationofcoreneedlebiopsyafterradiofrequencyablationforlowriskpapillarythyroidmicrocarcinomaalargecohortof202patientsstudy
AT zhuyaqiong theclinicalapplicationofcoreneedlebiopsyafterradiofrequencyablationforlowriskpapillarythyroidmicrocarcinomaalargecohortof202patientsstudy
AT xiaojing theclinicalapplicationofcoreneedlebiopsyafterradiofrequencyablationforlowriskpapillarythyroidmicrocarcinomaalargecohortof202patientsstudy
AT lanyu theclinicalapplicationofcoreneedlebiopsyafterradiofrequencyablationforlowriskpapillarythyroidmicrocarcinomaalargecohortof202patientsstudy
AT tianxiaoqi theclinicalapplicationofcoreneedlebiopsyafterradiofrequencyablationforlowriskpapillarythyroidmicrocarcinomaalargecohortof202patientsstudy
AT songqing theclinicalapplicationofcoreneedlebiopsyafterradiofrequencyablationforlowriskpapillarythyroidmicrocarcinomaalargecohortof202patientsstudy
AT xiefang theclinicalapplicationofcoreneedlebiopsyafterradiofrequencyablationforlowriskpapillarythyroidmicrocarcinomaalargecohortof202patientsstudy
AT yanlin clinicalapplicationofcoreneedlebiopsyafterradiofrequencyablationforlowriskpapillarythyroidmicrocarcinomaalargecohortof202patientsstudy
AT luoyukun clinicalapplicationofcoreneedlebiopsyafterradiofrequencyablationforlowriskpapillarythyroidmicrocarcinomaalargecohortof202patientsstudy
AT zhangying clinicalapplicationofcoreneedlebiopsyafterradiofrequencyablationforlowriskpapillarythyroidmicrocarcinomaalargecohortof202patientsstudy
AT zhuyaqiong clinicalapplicationofcoreneedlebiopsyafterradiofrequencyablationforlowriskpapillarythyroidmicrocarcinomaalargecohortof202patientsstudy
AT xiaojing clinicalapplicationofcoreneedlebiopsyafterradiofrequencyablationforlowriskpapillarythyroidmicrocarcinomaalargecohortof202patientsstudy
AT lanyu clinicalapplicationofcoreneedlebiopsyafterradiofrequencyablationforlowriskpapillarythyroidmicrocarcinomaalargecohortof202patientsstudy
AT tianxiaoqi clinicalapplicationofcoreneedlebiopsyafterradiofrequencyablationforlowriskpapillarythyroidmicrocarcinomaalargecohortof202patientsstudy
AT songqing clinicalapplicationofcoreneedlebiopsyafterradiofrequencyablationforlowriskpapillarythyroidmicrocarcinomaalargecohortof202patientsstudy
AT xiefang clinicalapplicationofcoreneedlebiopsyafterradiofrequencyablationforlowriskpapillarythyroidmicrocarcinomaalargecohortof202patientsstudy